Findings

What do systematic reviews say?

5 questions · 5 findings · 2 reviews · Vascular

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 60%Moderate 1 · 20%High 1 · 20%

Symptomatic DVT · ambulatory cancer patients receiving chemotherapy

DOAC showed no clear difference in symptomatic DVT compared with placebo (low certainty).

1 finding from 1 review

Symptomatic VTE · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

DOAC probably leads to lower symptomatic VTE (DVT and PE) Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).

1 finding from 1 review

Symptomatic VTE · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

DOAC showed no clear difference in symptomatic VTE (DVT and PE) Treatment duration 28 ‐ 42 days compared with heparin (low certainty).

1 finding from 1 review

Symptomatic DVT · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

DOAC leads to lower symptomatic DVT (proximal or distal) Treatment duration 28 ‐ 42 days compared with placebo (high certainty).

1 finding from 1 review

Symptomatic DVT · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair

DOAC showed no clear difference in symptomatic DVT (proximal or distal) Treatment duration 28 ‐ 42 days compared with heparin (low certainty).

1 finding from 1 review